• Monopar flagged a newly published peer-reviewed Phase 2 open-label study on ALXN1840 in Wilson disease, with results already presented in the journal article.
• The trial showed the drug rapidly improved copper control versus patients’ pre-treatment baseline, supporting its potential to reduce harmful copper build-up over time.
• Investigators reported the effect was sustained during the study period, with the improvement driven by greater elimination of copper through the digestive tract.
• The treatment was generally well tolerated, with no serious adverse events reported.
• Monopar framed the findings as supportive of prior Phase 3 evidence that ALXN1840 can outperform current standard treatments even in long-treated patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017821), on May 19, 2026, and is solely responsible for the information contained therein.